Skip to main content
SpringerLink
Log in

Montelukast

A Viewpoint by Carl Burgess and Julian Crane

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Spector SL. Leukotriene activity modulation in asthma. Drugs 1997; 54: 369–84

    Article  PubMed  CAS  Google Scholar 

  2. Reiss TF, White R, Noonan G, et al. Montelukast (MK-0476), A CysLT1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment [abstract]. Eur Resp J 1997 Sep; 10 Suppl. 25: 437s

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Wellington School of Medicine, Wellington, New Zealand

    Carl Burgess & Julian Crane

Authors
  1. Carl Burgess
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julian Crane
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burgess, C., Crane, J. Montelukast. Drugs 56, 257 (1998). https://doi.org/10.2165/00003495-199856020-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199856020-00012

Search

Navigation